image
Healthcare - Biotechnology - NASDAQ - US
$ 4.955
-8.92 %
$ 110 M
Market Cap
-2.27
P/E
1. INTRINSIC VALUE

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.[ Read More ]

The intrinsic value of one INMB stock under the base case scenario is HIDDEN Compared to the current market price of 4.96 USD, INmune Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INMB

image
FINANCIALS
155 K REVENUE
-58.56%
-29.7 M OPERATING INCOME
-14.60%
-30 M NET INCOME
-9.92%
-12 M OPERATING CASH FLOW
47.19%
0 INVESTING CASH FLOW
0.00%
-4.22 M FINANCING CASH FLOW
-579.56%
0 REVENUE
0.00%
-12.3 M OPERATING INCOME
-24.54%
-12.1 M NET INCOME
-24.08%
-6.99 M OPERATING CASH FLOW
11.41%
0 INVESTING CASH FLOW
0.00%
9.79 M FINANCING CASH FLOW
-24.66%
Balance Sheet Decomposition INmune Bio, Inc.
image
Current Assets 39.9 M
Cash & Short-Term Investments 35.8 M
Receivables 2.44 M
Other Current Assets 1.65 M
Non-Current Assets 17.1 M
Long-Term Investments 0
PP&E 414 K
Other Non-Current Assets 16.6 M
Current Liabilities 18.5 M
Accounts Payable 7.9 M
Short-Term Debt 10.2 M
Other Current Liabilities 405 K
Non-Current Liabilities 397 K
Long-Term Debt 397 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall INmune Bio, Inc.
image
Revenue 155 K
Cost Of Revenue 0
Gross Profit 155 K
Operating Expenses 29.9 M
Operating Income -29.7 M
Other Expenses 267 K
Net Income -30 M
RATIOS
100.00% GROSS MARGIN
100.00%
-19187.74% OPERATING MARGIN
-19187.74%
-19360.00% NET MARGIN
-19360.00%
-78.68% ROE
-78.68%
-52.64% ROA
-52.64%
-61.73% ROIC
-61.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis INmune Bio, Inc.
image
Net Income -30 M
Depreciation & Amortization 29.7 M
Capital Expenditures 0
Stock-Based Compensation 7.37 M
Change in Working Capital 10.4 M
Others 1.92 M
Free Cash Flow -12 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets INmune Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for INMB of $22 , with forecasts ranging from a low of $22 to a high of $22 .
INMB Lowest Price Target Wall Street Target
22 USD 344.00%
INMB Average Price Target Wall Street Target
22 USD 344.00%
INMB Highest Price Target Wall Street Target
22 USD 344.00%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership INmune Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
348 K USD 2
0-3 MONTHS
36.4 K USD 1
3-6 MONTHS
1.4 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Sep 30, 2024
Bought 52.9 K USD
Moss David J
Chief Financial Officer
+ 10000
5.2868 USD
2 months ago
Sep 12, 2024
Bought 98 K USD
Tesi Raymond Joseph
President and CEO
+ 15380
6.375 USD
2 months ago
Sep 12, 2024
Bought 98.4 K USD
Tesi Raymond Joseph
President and CEO
+ 15380
6.4 USD
2 months ago
Sep 12, 2024
Bought 49 K USD
Moss David J
Chief Financial Officer
+ 7690
6.375 USD
2 months ago
Sep 12, 2024
Bought 49.2 K USD
Moss David J
Chief Financial Officer
+ 7690
6.4 USD
4 months ago
Jun 25, 2024
Bought 36.4 K USD
Juda Scott
Director
+ 5000
7.27 USD
6 months ago
Apr 19, 2024
Bought 150 K USD
Moss David J
CFO, Treasurer & Secretary
+ 18028
8.32 USD
6 months ago
Apr 19, 2024
Bought 165 K USD
Moss David J
CFO, Treasurer & Secretary
+ 18028
9.152 USD
6 months ago
Apr 19, 2024
Bought 150 K USD
Tesi Raymond Joseph
President and CEO
+ 18028
8.32 USD
6 months ago
Apr 19, 2024
Bought 165 K USD
Tesi Raymond Joseph
President and CEO
+ 18028
9.152 USD
6 months ago
Apr 19, 2024
Bought 120 K USD
Lowdell Mark William
Chief Scientific Officer
+ 14423
8.32 USD
6 months ago
Apr 19, 2024
Bought 132 K USD
Lowdell Mark William
Chief Scientific Officer
+ 14423
9.152 USD
6 months ago
Apr 19, 2024
Bought 246 K USD
Juda Scott
Director
+ 29603
8.32 USD
6 months ago
Apr 19, 2024
Bought 271 K USD
Juda Scott
Director
+ 29603
9.152 USD
1 year ago
Nov 10, 2023
Bought 48.6 K USD
Juda Scott
Director
+ 7000
6.95 USD
1 year ago
Jul 12, 2023
Sell 110 K USD
Schroeder Timothy j
Director
- 10000
11.0085 USD
1 year ago
Mar 17, 2023
Bought 16.1 K USD
Moss David J
CFO, Treasurer & Secretary
+ 2500
6.425 USD
2 years ago
May 26, 2022
Bought 40.4 K USD
Tesi Raymond Joseph
President and CEO
+ 6300
6.41 USD
2 years ago
May 26, 2022
Bought 48.3 K USD
Moss David J
CFO, Treasurer & Secretary
+ 7700
6.27 USD
3 years ago
Nov 17, 2021
Bought 33.9 K USD
Juda Scott
Director
+ 2500
13.55 USD
3 years ago
Nov 03, 2021
Sell 14 K USD
Lowdell Mark William
Chief Scientific Officer
- 701
20 USD
3 years ago
Nov 03, 2021
Sell 20.5 K USD
Moss David J
CFO, Treasurer & Secretary
- 1025
20 USD
3 years ago
Nov 03, 2021
Sell 72.5 K USD
Tesi Raymond Joseph
President and CEO
- 3626
20 USD
3 years ago
Oct 27, 2021
Sell 130 K USD
Tesi Raymond Joseph
President and CEO
- 6517
20 USD
3 years ago
Oct 27, 2021
Sell 47.1 K USD
Lowdell Mark William
Chief Scientific Officer
- 2357
20 USD
3 years ago
Oct 27, 2021
Sell 41.6 K USD
Moss David J
CFO, Treasurer & Secretary
- 2079
20 USD
3 years ago
Oct 22, 2021
Sell 472 K USD
Tesi Raymond Joseph
President and CEO
- 23616
20 USD
3 years ago
Oct 22, 2021
Sell 22.8 K USD
Moss David J
CFO, Treasurer & Secretary
- 1142
20 USD
3 years ago
Oct 22, 2021
Sell 260 USD
Moss David J
CFO, Treasurer & Secretary
- 13
20 USD
3 years ago
Oct 22, 2021
Sell 8 K USD
Lowdell Mark William
Chief Scientific Officer
- 400
20 USD
3 years ago
Jul 13, 2021
Sell 400 K USD
Schroeder Timothy j
Director
- 14480
27.63 USD
3 years ago
Jul 09, 2021
Sell 696 K USD
Schroeder Timothy j
Director
- 30000
23.205 USD
3 years ago
Jul 07, 2021
Sell 117 K USD
Lowdell Mark William
Chief Scientific Officer
- 5850
20.02 USD
3 years ago
Jul 07, 2021
Sell 488 K USD
Lowdell Mark William
Chief Scientific Officer
- 24150
20.19 USD
3 years ago
Jul 07, 2021
Sell 174 K USD
Moss David J
CFO, Treasurer & Secretary
- 8698
20.0081 USD
3 years ago
Jul 07, 2021
Sell 327 K USD
Moss David J
CFO, Treasurer & Secretary
- 16302
20.0891 USD
3 years ago
Jul 07, 2021
Sell 113 K USD
Tesi Raymond Joseph
President and CEO
- 5649
20.018 USD
3 years ago
Jul 07, 2021
Sell 489 K USD
Tesi Raymond Joseph
President and CEO
- 24351
20.08 USD
3 years ago
Jun 14, 2021
Sell 190 K USD
Schroeder Timothy j
Director
- 10000
19.02 USD
3 years ago
Jun 10, 2021
Sell 170 K USD
Schroeder Timothy j
Director
- 10000
17.0054 USD
3 years ago
Mar 31, 2021
Sell 119 K USD
Schroeder Timothy j
Director
- 10000
11.9496 USD
4 years ago
Jan 27, 2020
Sell 1.01 M USD
Powers Linda F
Director
- 220000
4.6 USD
5 years ago
Sep 11, 2019
Bought 18.2 K USD
Lowdell Mark William
Chief Scientific Officer
+ 2918
6.2298 USD
5 years ago
Aug 20, 2019
Bought 15 K USD
Juda Scott
Director
+ 2500
6 USD
5 years ago
Aug 20, 2019
Bought 15 K USD
Juda Scott
Director
+ 2500
6 USD
5 years ago
Aug 20, 2019
Bought 2.12 K USD
Moss David J
CFO, Treasurer & Secretary
+ 376
5.65 USD
5 years ago
Aug 20, 2019
Bought 1.33 K USD
Moss David J
CFO, Treasurer & Secretary
+ 236
5.65 USD
5 years ago
Aug 20, 2019
Bought 407 USD
Moss David J
CFO, Treasurer & Secretary
+ 72
5.65 USD
5 years ago
Aug 20, 2019
Bought 11.3 K USD
Moss David J
CFO, Treasurer & Secretary
+ 2000
5.65 USD
5 years ago
Aug 20, 2019
Bought 1.35 K USD
Moss David J
CFO, Treasurer & Secretary
+ 239
5.65 USD
5 years ago
Aug 20, 2019
Bought 435 USD
Moss David J
CFO, Treasurer & Secretary
+ 77
5.65 USD
5 years ago
Aug 20, 2019
Bought 6.03 K USD
Tesi Raymond Joseph
President & CEO
+ 1000
6.0308 USD
5 years ago
Aug 20, 2019
Bought 592 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.9239 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 20, 2019
Bought 596 USD
Tesi Raymond Joseph
President & CEO
+ 100
5.96 USD
5 years ago
Aug 09, 2019
Bought 6.91 K USD
Tesi Raymond Joseph
President & CEO
+ 1000
6.9095 USD
5 years ago
Aug 09, 2019
Bought 6.43 K USD
Tesi Raymond Joseph
President & CEO
+ 900
7.1431 USD
5 years ago
Aug 09, 2019
Bought 720 USD
Tesi Raymond Joseph
President & CEO
+ 100
7.2 USD
5 years ago
Jun 03, 2019
Bought 60 K USD
Powers Linda F
Director
+ 10000
6 USD
5 years ago
Jun 03, 2019
Bought 60 K USD
Juda Scott
Director
+ 10000
6 USD
5 years ago
Jun 03, 2019
Bought 60 K USD
Moss David J
director: CFO, Treasurer & Secretary
+ 10000
6 USD
5 years ago
Jun 03, 2019
Bought 60 K USD
Tesi Raymond Joseph
director: President & CEO
+ 10000
6 USD
5 years ago
May 02, 2019
Bought 119 K USD
Tesi Raymond Joseph
director: President & CEO
+ 11100
10.75 USD
5 years ago
May 06, 2019
Bought 53.6 K USD
Moss David J
director: CFO, Treasurer & Secretary
+ 5000
10.71 USD
5 years ago
May 08, 2019
Bought 555 K USD
Powers Linda F
Director
+ 61667
9 USD
5 years ago
May 02, 2019
Bought 99.9 K USD
Tesi Raymond Joseph
director: President & CEO
+ 11100
9 USD
5 years ago
May 06, 2019
Bought 45 K USD
Moss David J
director: CFO, Treasurer & Secretary
+ 5000
9 USD
5 years ago
May 02, 2019
Bought 110 K USD
Tesi Raymond Joseph
director: Chairman
+ 11100
9.9 USD
7. News
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Gary Nachman - Raymond James George Farmer - Scotiabank Joel Beatty - Baird Thomas Shrader - BTIG Operator Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. seekingalpha.com - 2 weeks ago
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. globenewswire.com - 2 weeks ago
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB “Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET. globenewswire.com - 2 weeks ago
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell globenewswire.com - 3 weeks ago
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update. globenewswire.com - 3 weeks ago
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --    INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024. globenewswire.com - 1 month ago
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate resistant prostate cancer market is projected to reach $20.70 billion by 2031. INMB completed enrollment of AD02 Phase 2 study, using XPro for patients with Alzheimer's Disease expected in Q3 of 2024, with clinical data expected 6 months after last patient recruited. seekingalpha.com - 1 month ago
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial. globenewswire.com - 1 month ago
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated  exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials. globenewswire.com - 2 months ago
INmune Bio Announces $13.0 Million Registered Direct Offering Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the “Insiders”), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant. globenewswire.com - 2 months ago
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024. globenewswire.com - 2 months ago
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG George Farmer - Scotiabank Operator Greetings, and welcome to the INmune Bio Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
8. Profile Summary

INmune Bio, Inc. INMB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 110 M
Dividend Yield 0.00%
Description INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Contact 225 NE Mizner Boulevard, Boca Raton, FL, 33432 https://www.inmunebio.com
IPO Date Feb. 4, 2019
Employees 11
Officers Mr. Joshua S. Schoonover Esq. General Counsel Dr. Raymond Joseph Tesi M.D. Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman Mr. David J. Moss M.B.A. Chief Financial Officer, Treasurer & Secretary Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer